Home » Stocks » China Biologic Products

China Biologic Products Holdings, Inc. (CBPO)

Stock Price: $106.11 USD 0.08 (0.08%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $106.60 +0.49 (0.46%) Aug 11, 5:00 PM

Stock Price Chart

Key Info

Market Cap 4.08B
Revenue (ttm) 536.55M
Net Income (ttm) 154.50M
Shares Out 38.46M
EPS (ttm) 3.95
PE Ratio 26.86
Forward PE 21.01
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $106.11
Previous Close $106.03
Change ($) 0.08
Change (%) 0.08%
Day's Open 106.10
Day's Range 106.03 - 107.98
Day's Volume 46,064
52-Week Range 93.90 - 119.44

More Stats

Market Cap 4.08B
Enterprise Value 3.09B
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.46M
Float 14.18M
EPS (basic) 3.99
EPS (diluted) 3.95
FCF / Share 6.64
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.72%
FCF Yield 6.26%
Payout Ratio n/a
Shares Short 448,267
Short Ratio 3.24
Short % of Float 2.09%
Beta 0.82
PE Ratio 26.86
Forward PE 21.01
P/FCF Ratio 15.99
PS Ratio 7.61
PB Ratio 2.35
Revenue 536.55M
Operating Income 187.79M
Net Income 154.50M
Free Cash Flow 255.43M
Net Cash 991.63M
Net Cash / Share 25.77
Gross Margin 61.33%
Operating Margin 35.00%
Profit Margin 28.80%
FCF Margin 47.61%
ROA 5.84%
ROE 9.80%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

(3.69% upside)
Current: $106.11
Target: 110.03
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth7.9%26.04%8.57%15.08%21.87%19.62%10.03%20.72%9.59%-
Gross Profit329320245217190163138126107103
Operating Income16414613614413311186.9374.4932.2268.57
Net Income13912867.9410589.0470.9254.6045.2218.1831.54
Shares Outstanding38.6635.3027.3626.8525.6024.4326.4126.1525.0323.59
Earnings Per Share3.533.532.383.743.272.711.961.620.371.30
EPS Growth0%48.32%-36.36%14.37%20.66%38.27%20.99%337.84%-71.54%-
Operating Cash Flow22910410212310993.5174.3071.1038.4738.79
Capital Expenditures-19.72-31.62-37.44-38.68-37.96-15.34-20.30-13.80-7.91-10.31
Free Cash Flow21072.3264.7484.5871.4378.1854.0157.2930.5628.47
Cash & Equivalents92795228818418318518113389.4164.94
Total Debt-----97.9039.827.9411.024.23
Net Cash / Debt92795228818418386.8314112578.3960.71
Book Value1,6961,72259846238221223819513699.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name China Biologic Products Holdings, Inc.
Country China
Employees 2,246
CEO Joseph Chow

Stock Information

Ticker Symbol CBPO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBPO


China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.